NED Biosystems
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 18, Cambridge, Massachuse...Phone Number
(857) 285-2120Website
www.nedbiosystems.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NED Biosystems
NED Biosystems is a clinical-stage Public Benefit Corporation focused on developing innovative cancer treatments, particularly through its patented NED-170 therapy. The company employs a systems-based approach to target the entire biological system, aiming to provide safe and effective therapies with minimal toxicity. In addition to cancer treatments, NED is also developing NED-260, a universal antiviral treatment for various infectious diseases. NED Biosystems is committed to ensuring access to effective therapies for all patients, regardless of their background.Explore more
NED Biosystems Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NED Biosystems your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NED Biosystems launches new products
Earning: See what the market has to say on NED Biosystems recently announced quarterly report
Check if NED Biosystems has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NED Biosystems has new funding data
Website visits: Recent activity has been detected on your website
NED Biosystems, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if NED Biosystems had a recent Job posting/layoffs
Check out if NED Biosystems is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at NED Biosystems
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NED Biosystems
Compare insights from companies similar to NED Biosystems, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NED Biosystems is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NED Biosystems is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NED Biosystems.
NED Biosystems financials insights
Gather financial insights about NED Biosystems, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series B
$2M
2021
Debt
$64K
NED Biosystems Tech Stack
A closer look at the technologies used by NED Biosystems
See more technologies
NED Biosystems News & Media
Founding Director of DARPA Biological Technologies Office, Geoffrey Ling, Appointed CEO of NED Biosystems™
CAMBRIDGE, Mass., July 10, 2019 /PRNewswire/ -- NED Biosystems, a clinical-stage biotech company investigating solutions for a broad range of cancers, is pleased to announce Geoffrey Ling, MD, PhD, Col. (Ret.), has been named CEO. He is both a physician and pharmacologist. A former U.S....First-of-its-kind Composition Patent Awarded to NED Biosystems for 7-Agent Combination Cancer Therapeutic
CAMBRIDGE, Mass., Feb. 7, 2019 /PRNewswire/ -- NED Biosystems, a clinical-stage biotech company investigating solutions for a range of cancers, today announced that the U.S. Patent and Trademark Office has awarded the company patent number 10,195,219 for its lead investigational...NED Biosystems Raises $2 Million in Series B Financing Round and Appoints New CEO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NED Biosystems, a clinical-stage biotech company developing a unique oral oncologic combination treatment that simultaneously attacks 5 cancer-driving processes, today announced it has raised over $2 million toward its Series B round of financing which includes funding from new and existing company investors. Significant investors in this round include Benjamin Griswold IV, Chairman of Brown Advisory, an independent Baltimore-based investment firm. The funds r
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NED Biosystems
Sign Up For FreeTo access detailed company insights
NED Biosystems is a clinical-stage Public Benefit Corporation focused on developing innovative cancer treatments, particularly through its patented NED-170 therapy. The company employs a systems-based approach to target the entire biological system, aiming to provide safe and effective therapies with minimal toxicity. In addition to cancer treatmen... Read More
